Stock SIGHT GENSIGHT BIOLOGICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

News GenSight Biologics S.A.

Equities

SIGHT

FR0013183985

Market Closed - Euronext Paris
Other stock markets
 11:35:15 2024-04-18 am EDT 		5-day change 1st Jan Change
0.41 EUR -2.84% Intraday chart for GenSight Biologics S.A. +2.50% -10.87%
Apr. 05 GenSight: financial visibility assured until the end of April CF
Mar. 25 GenSight: share price falls, limited financial visibility CF

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
GenSight Biologics S A : Inside Information / News release on accounts, results
PU
GenSight Biologics Announces the Filing of its 2023 Universal Registration Document
BU
GenSight Biologics S A : Announces the Filing of its 2023 Universal Registration Document
PU
GenSight: financial visibility assured until the end of April
CF
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update
BU
GenSight Biologics Announces its 2024 Financial Calendar
BU
GenSight Biologics S A : Reports Cash Position as of March 31, 2024, and Provides Business Update
PU
GenSight Biologics S A : Announces Its 2024 Financial Calendar
PU
GenSight: share price falls, limited financial visibility
CF
GenSight Biologics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
GenSight Biologics Reports Full Year 2023 Consolidated Financial Results
BU
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration
BU
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ®? Injections Four Years After One-Time Administration
CI
GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ Gene Therapy at NANOS 2024
AQ
GenSight Biologics: results on Lumevoq® gene therapy
CF
GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024
BU
GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024
CI
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ Gene Therapy at NANOS 2024
AQ
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024
BU
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SIGHT Stock
  4. News GenSight Biologics S.A.